Your browser doesn't support javascript.
loading
Lipopolysaccharide-binding protein in Crohn's disease patients: a promising noninvasive biomarker monitoring disease activity.
Toris, Louison D; Minsart, Charlotte F; Husson, Cécile P; Franchimont, Denis P; Liefferinckx, Claire L.
Afiliación
  • Toris LD; Laboratory of Gastroenterology Experimental (LGE), Université Libre de Bruxelles (ULB).
  • Minsart CF; Laboratory of Gastroenterology Experimental (LGE), Université Libre de Bruxelles (ULB).
  • Husson CP; Department of Gastroenterology - Hepato-Pancreatology and Digestive Oncology, Université libre de Bruxelles ULB - Hôpital Universitaire de Bruxelles H.U.B - CUB Hôpital Erasme, Brussels, Belgium.
  • Franchimont DP; Laboratory of Gastroenterology Experimental (LGE), Université Libre de Bruxelles (ULB).
  • Liefferinckx CL; Laboratory of Gastroenterology Experimental (LGE), Université Libre de Bruxelles (ULB).
Eur J Gastroenterol Hepatol ; 36(9): 1093-1100, 2024 Sep 01.
Article en En | MEDLINE | ID: mdl-38976551
ABSTRACT

BACKGROUND:

Following STRIDE-II recommendations, the discovery of novel noninvasive biomarkers, beyond the use of C-reactive protein (CRP) and fecal calprotectin, remains a medical need to further improve the monitoring of patients with inflammatory bowel disease (IBD). This study aims to evaluate the potential of serum lipopolysaccharide-binding protein (LBP) in monitoring IBD activity.

METHODS:

This retrospective cross-sectional study included 69 IBD patients (43 Crohn's disease and 26 ulcerative colitis) and 82 controls. Serum LBP levels were measured by ELISA. Clinical, biological and endoscopic parameters were analyzed for IBD patients with no reports of missing data. Statistical tests, including nonparametric tests and receiver operating characteristic (ROC) curve analysis, were used to evaluate the diagnostic accuracy of LBP.

RESULTS:

IBD patients displayed a significantly higher LBP median [29.6 µg/ml (19.8-38.8) in Crohn's disease and 22.8 (13.7-38.8) in ulcerative colitis] than controls [5.8 (4.7-7.3), P  < 0.001] with little overlapping distributions. In Crohn's disease patients, LBP levels gradually increased with endoscopic activity scores demonstrating a 1.7-fold rise in active patients compared to remitter patients ( P  = 0.02). LBP level exhibited a positive correlation with CRP ( ρ  = 0.75, P  < 0.001) as well as fecal calprotectin ( ρ  = 0.42, P  < 0.01), both of which further increased when excluding cases that did not match endoscopic activity.

CONCLUSION:

LBP might be a promising noninvasive biomarker for monitoring disease activity, especially in Crohn's disease patients. In clinical situations where current biomarkers lack sensitivity, LBP could be discriminative and help filling the gap for reliable therapeutic decisions.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Proteínas de Fase Aguda / Glicoproteínas de Membrana / Biomarcadores / Proteínas Portadoras / Colitis Ulcerosa / Enfermedad de Crohn Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Proteínas de Fase Aguda / Glicoproteínas de Membrana / Biomarcadores / Proteínas Portadoras / Colitis Ulcerosa / Enfermedad de Crohn Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido